Abstract

In clinical diagnosis and treatment, it is very important to distinguish cancer cells from normal cells. Nuclear-selective fluorescent probe that specifically target tumors can not only make the difference in assessing tumor margins during surgery and then facilitating accurate resection of the tumor, but also can provide crucial biomedical information of tumor progress if it can be used for long-term dynamic visualization of nucleus in cancer. Herein, a novel fluorescent probe 3 was designed and characterized to be of low-toxicity and water-solubility. The biological evaluation indicated that probe 3 prefers nucleic acids rather than accumulation in non-neuclear sites while superior to the commercial available agent DAPI (4',6-diamidino-2-phenylindole), in terms of its character of aggregation-induced emission (AIE), large Stokes shift (175 nm) and light stability. Further experiments demonstrated that probe 3 can not only differentiate SW480 and SW620 (cancer cells) from GES-1 (normal cells) with high contrast (dyed in nuclear of cancer cells and not in nuclear of normal cells), but also used for tracking cancer cell nuclear for long time. Furthermore, 3D reconstruction fluorescence imaging proved that probe 3 was able for identifying colorectal cancer tissues from para-carcinoma tissues by a strong contrast. Therefore, in precise surgery of colorectal cancer, probe 3 may be a promising-agent for guiding of intraoperation.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.